



NewTherapiesSubgroup



Date of original recommendation: 23rd March 2010
Date Re-reviewed: April 17th 2014.

Lidocaine 5% plaster (Versatis®) for the treatment of postherpatic neuralgia (PHN)

The Interface Prescribing and New Therapies Subgroup discussed the above drug at a meeting on 25th September 2012. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMM considered the use of lidocaine plaster (Versatis®) for the treatment of postherpatic neuralgia.

The group does not recommend the use of lidocaine plasters for the above indication.

The group felt that efficacy and cost effectiveness of the product in comparison to other agents had yet to be proven.

The group is aware that lidocaine plaster is also currently used 'off label' for indications other than treatment of postherpatic neuralgia and the group do not recommend this 'off label' use for the reasons outlined above.

According to set criteria lidocaine plasters were deemed to be a low priority for funding

Review date: April 2016

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.